TY - JOUR
T1 - Structural Analysis of Heparin-Derived 3-O-Sulfated Tetrasaccharides
T2 - Antithrombin Binding Site Variants
AU - Chen, Yin
AU - Lin, Lei
AU - Agyekum, Isaac
AU - Zhang, Xing
AU - St. Ange, Kalib
AU - Yu, Yanlei
AU - Zhang, Fuming
AU - Liu, Jian
AU - Amster, I. Jonathan
AU - Linhardt, Robert J.
N1 - Publisher Copyright:
© 2017 American Pharmacists Association®
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Heparin is a polysaccharide that is widely used as an anticoagulant drug. The mechanism for heparin's anticoagulant activity is primarily through its interaction with a serine protease inhibitor, antithrombin III (AT), that enhances its ability to inactivate blood coagulation serine proteases, including thrombin (factor IIa) and factor Xa. The AT-binding site in the heparin is one of the most well-studied carbohydrate-protein binding sites and its structure is the basis for the synthesis of the heparin pentasaccharide drug, fondaparinux. Despite our understanding of the structural requirements for the heparin pentasaccharide AT-binding site, there is a lack of data on the natural variability of these binding sites in heparins extracted from animal tissues. The present work provides a detailed study on the structural variants of the tetrasaccharide fragments of this binding site afforded following treatment of a heparin with heparin lyase II. The 5 most commonly observed tetrasaccharide fragments of the AT-binding site are fully characterized, and a method for their quantification in heparin and low-molecular-weight heparin products is described.
AB - Heparin is a polysaccharide that is widely used as an anticoagulant drug. The mechanism for heparin's anticoagulant activity is primarily through its interaction with a serine protease inhibitor, antithrombin III (AT), that enhances its ability to inactivate blood coagulation serine proteases, including thrombin (factor IIa) and factor Xa. The AT-binding site in the heparin is one of the most well-studied carbohydrate-protein binding sites and its structure is the basis for the synthesis of the heparin pentasaccharide drug, fondaparinux. Despite our understanding of the structural requirements for the heparin pentasaccharide AT-binding site, there is a lack of data on the natural variability of these binding sites in heparins extracted from animal tissues. The present work provides a detailed study on the structural variants of the tetrasaccharide fragments of this binding site afforded following treatment of a heparin with heparin lyase II. The 5 most commonly observed tetrasaccharide fragments of the AT-binding site are fully characterized, and a method for their quantification in heparin and low-molecular-weight heparin products is described.
KW - anticoagulant activity
KW - antithrombin-binding site
KW - heparin lyase
KW - heparin-derived tetrasaccharides
KW - structure-activity relationship
UR - http://www.scopus.com/inward/record.url?scp=85009433529&partnerID=8YFLogxK
U2 - 10.1016/j.xphs.2016.11.023
DO - 10.1016/j.xphs.2016.11.023
M3 - Article
C2 - 28007564
AN - SCOPUS:85009433529
SN - 0022-3549
VL - 106
SP - 973
EP - 981
JO - Journal of Pharmaceutical Sciences
JF - Journal of Pharmaceutical Sciences
IS - 4
ER -